News file for: Pfizer Inc
The approval of Baiyunshan’s generic Viagra could help it attain market dominance in China’s erectile dysfunction sector.
Oxford Global’s Pharmaceutical IT Asia Congress will take place from March 25-26, 2014 in Singapore..
Pfizer and Takeda Pharmaceutical have launched their rheumatoid arthritis drug XELJANZ® (tofacitinib citrate) in Japan.
Pfizer Inc. will conduct a clinical trial of its crizotinib drug, marketed under the trademark Xalkori®, in four Asian countries.
Pfizer Inc. and Mylan Inc. have signed an agreement to develop, manufacture, distribute, and market generic drugs in Japan.
Pfizer Inc. and Zhejiang Hisun Pharmaceutical have agreed to jointly develop, manufacture, and commercialize off-patent pharmaceutical products in China and global markets.
A large coalition of pharmas, governments, and NGOs have announced their goal of eliminating or controlling 10 neglected tropical diseases by 2020.
SFJ Pharma Ltd. will conduct a Phase III clinical trial in Asia of Pfizer’s axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy.
Pfizer Animal Health and The Resource Foundation will help to increase the capacity, productivity, and quality of life of rural farmers in India and Latin America.
Pfizer And Guoyuan have formed a joint venture to expand development, manufacture, and distribution of animal vaccines in China, with an initial focus on swine vaccines.